A French pharmaceutical company is hoping to reap massive profits from a new drug patch that it says treats a common food allergy caused by vaccines. The DBV Technologies SA Viaskin Peanut patch for peanut allergy currently holds a market value of $1 billion, according to reports, which represents yet another major profit stream for an industry that creates many of the diseases it treats.
In this case, the ongoing peanut allergy epidemic, which is largely the result of peanut oil being used in vaccines as an adjuvant, is a major target of the money-hungry drug cartels. Whichever corporation can come up with the most effective “blockbuster” drug to treat this horrific illness, which currently afflicts more than 4.5 million people, will have the potential to rake in billions in profits.
The Viaskin Peanut patch is one viable contender that its manufacturer’s CFO hopes to begin producing commercially following clinical trials. With a $100 million investment from its own coffers, DBV is trying to avoid having to receive funding from other drug companies, and instead pocket all of the cash for itself.
“It would be a shame to involve a big pharmaceutical company that would pocket two-thirds of the value,” stated Chief Financial Officer David Schilansky to Bloomberg about the drug. “We have the money, so we can do as we please.”
The real shame, though, is the history of peanut allergy itself. In her new book The History of the Peanut Allergy Epidemic, Heather Fraser explains how peanut allergy has its roots in mass vaccinations foisted on the general public by the very same industry that is now trying to profit from treating it.
Peanut allergy associated with vaccinations leads to profit for patch-peddling pharmaceutical company
Posted on June 7, 2016 by Boulderdash